MRTX News and Press, Mirati Therapeutics Inc. From 05/04/22

Mirati Therapeutics, Inc. (MRTX) Q1 2022 Earnings Conference Call May 04, 2022, 04:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - CEO James Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Vickie Reed - CAO Daniel Faga - ...

Mirati Therapeutics press release (NASDAQ:MRTX): Q1 GAAP EPS of -$3.40 beats by $0.17. Revenue of $0.71M beats by $0.53M. For further details see: Mirati Therapeutics GAAP EPS of -$3.40 beats by $0.17, revenue of $0.71M beats by $0.53M

Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , May 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported fina...

Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib PR Newswire Full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 stud...

Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , April 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce ...

Mirati has a PDUFA on December 14. Lumakras is already approved conditionally, with confirmatory data this year. While adagrasib is marginally better in NSCLC, the real fight is in CRC and pancreatic cancer. For further details see: Mirati: Can Adagrasib Beat Amgen's Lum...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Baron is an asset management firm focused on delivering growth equity investment solutions known for long-term, fundamental, active approach to growth investing. The market and its herd of traders find themselves hyper-focused on reacting. The fundamentals and growth opportunities...

Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference PR Newswire SAN DIEGO , March 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat...

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated metastatic colorectal cancer patients with a 29% objective response rate. The global market opportunity for colorectal cancer is expected to reach $17.8 billion by 2026. About 50% o...